{"organizations": [], "uuid": "9a30513fd1304124d4ef2b9daf07aa15790e7550", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180517.html", "section_title": "Archive News &amp; Video for Thursday, 17 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-says-making-list-of-cos-blocki/brief-fda-says-making-list-of-cos-blocking-access-to-samples-of-branded-products-idUSFWN1SO0V0", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Says Making List Of Cos Blocking Access To Samples Of Branded Products", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.232, "site_type": "news", "published": "2018-05-17T22:33:00.000+03:00", "replies_count": 0, "uuid": "9a30513fd1304124d4ef2b9daf07aa15790e7550"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-says-making-list-of-cos-blocki/brief-fda-says-making-list-of-cos-blocking-access-to-samples-of-branded-products-idUSFWN1SO0V0", "ord_in_thread": 0, "title": "BRIEF-FDA Says Making List Of Cos Blocking Access To Samples Of Branded Products", "locations": [], "entities": {"persons": [{"name": "scott gottlieb", "sentiment": "negative"}, {"name": "gottlieb", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "danco", "sentiment": "none"}, {"name": "hyperion therapeutics", "sentiment": "none"}, {"name": "lundbeck llc", "sentiment": "none"}, {"name": "biogen idec", "sentiment": "none"}, {"name": "vivus inc", "sentiment": "none"}, {"name": "meda pharma", "sentiment": "none"}, {"name": "actelion pharma", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}, {"name": "novartis pharma", "sentiment": "none"}, {"name": "smithkline beecham", "sentiment": "none"}, {"name": "celgene", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 17 (Reuters) - FDA:\n* FDA COMMISSIONER SCOTT GOTTLIEB SAYS MAKING PUBLIC LIST OF COS THAT HAVE POTENTIALLY BEEN BLOCKING ACCESS TO THE SAMPLES OF THEIR BRANDED PRODUCTS\n* FDA’S GOTTLIEB - ALSO NOTIFYING FEDERAL TRADE COMMISSION ABOUT INQUIRIES RECEIVED FROM GENERIC DRUG DEVELOPERS\n* FDA’S GOTTLIEB - FDA WILL DETERMINE WHETHER THE PRODUCTS HAVE IN PLACE RISK EVALUATION & MITIGATION STRATEGY PROGRAM WITH ETASU THAT MAY IMPACT DISTRIBUTION\n* FDA’S GOTTLIEB SAYS IN MANY CASES, WE FIND THAT THERE’S NO SUCH REMS PROGRAM IN PLACE\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE NOVARTIS PHARMA, ACTELION PHARMA, VALEANT, SMITHKLINE BEECHAM, GILEAD, CELGENE\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BIOGEN IDEC, INSYS THERAPEUTICS, LUNDBECK LLC, HYPERION THERAPEUTICS, VIVUS INC\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE PFIZER PHARMACEUTICALS PRODUCTION, SWEDISH ORPHAN BIOVITRUM, MEDA PHARMA\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE DANCO LABORATORIES, ROXANE LABORATORIES, CORCEPT THERAPEUTICS, AEGERION PHARMA\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE PHARMACIA AND UPJOHN CO, QUESTCOR PHARMACEUTICALS, BOEHRINGER INGELHEIM, NPS PHARMA\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE SHIRE ORPHAN THERAPIES, APOPHARMA, CEPHALON INC, JAZZ PHARMA, CUBIST PHARMA\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE TEVA PHARMA USA, ALPHARMA PHARMA, ORPHAN EUROPE SARL, HERITAGE LIFE SCIENCES\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE ASTRAZENECA LP, ACORDA THERAPEUTICS, MYLAN PHARMA, NOVARTIS PHARMA\n* FDA’S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BAYER HEALTHCARE PHARMA, ROCHE PALO ALTO, GALENA BIOPHARMA\n* FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE RANBAXY INC/SUN PHARMACEUTICAL INDUSTRIES INC Source text : ( bit.ly/2rRalSM ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "http://bit.ly/2rRalSM"], "published": "2018-05-17T22:33:00.000+03:00", "crawled": "2018-05-18T19:43:31.020+03:00", "highlightTitle": ""}